CL2017003295A1 - Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias - Google Patents

Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias

Info

Publication number
CL2017003295A1
CL2017003295A1 CL2017003295A CL2017003295A CL2017003295A1 CL 2017003295 A1 CL2017003295 A1 CL 2017003295A1 CL 2017003295 A CL2017003295 A CL 2017003295A CL 2017003295 A CL2017003295 A CL 2017003295A CL 2017003295 A1 CL2017003295 A1 CL 2017003295A1
Authority
CL
Chile
Prior art keywords
lymphocytosis
leukemias
lymphomas
induction
antibodies against
Prior art date
Application number
CL2017003295A
Other languages
English (en)
Inventor
Christian Klein
Carola Ries
Maria Teresa Sabrina Bertilaccio
Giovanni Galletti
CALIGARIS-CAPPIO Federico
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15173638.6A external-priority patent/EP3108897A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017003295A1 publication Critical patent/CL2017003295A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A LA LINFOCITOSIS INDUCIDA POR ANTI-CSF-1R EN LINFOMAS Y LEUCEMIAS Y A UNA TERAPIA COMBINADA DE ANTICUERPOS QUE SE UNEN A CSF-1R HUMANO CON ANTICUERPOS QUE SE UNEN A CD20 HUMANO.</p>
CL2017003295A 2015-06-24 2017-12-21 Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias CL2017003295A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15173638.6A EP3108897A1 (en) 2015-06-24 2015-06-24 Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
EP16151129 2016-01-13

Publications (1)

Publication Number Publication Date
CL2017003295A1 true CL2017003295A1 (es) 2018-06-01

Family

ID=56263686

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003295A CL2017003295A1 (es) 2015-06-24 2017-12-21 Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias

Country Status (17)

Country Link
US (1) US20180222985A1 (es)
EP (1) EP3313442B1 (es)
JP (1) JP6811733B2 (es)
KR (1) KR20180012873A (es)
CN (1) CN107847592B (es)
AU (1) AU2016282877A1 (es)
BR (1) BR112017027614A2 (es)
CA (1) CA2987716A1 (es)
CL (1) CL2017003295A1 (es)
CR (1) CR20170537A (es)
HK (1) HK1252860A1 (es)
IL (1) IL256135A (es)
MX (1) MX2017016651A (es)
PE (1) PE20181050A1 (es)
RU (1) RU2018102575A (es)
WO (1) WO2016207312A1 (es)
ZA (1) ZA201708074B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
MX2019011748A (es) * 2017-04-01 2020-01-23 Beijing hanmi pharm co ltd Anticuerpo biespecífico heterodimérico tipo estructura de anticuerpo natural anti-pd-l1/anti-pd-1 y preparación del mismo.
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
AU2018314765A1 (en) 2017-08-08 2020-01-30 F. Hoffmann-La Roche Ag Obinutuzumab treatment of a DLBCL patient subgroup
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
CN109053886B (zh) * 2018-07-18 2020-07-28 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及用途
CN109053888B (zh) * 2018-07-18 2020-06-19 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及其用途
CA3113826A1 (en) 2018-09-27 2020-04-02 Marengo Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2348051T (lt) * 2003-11-05 2019-02-25 Roche Glycart Ag Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
US20070071745A1 (en) * 2005-08-26 2007-03-29 Pablo Umana Modified antigen binding molecules with altered cell signaling activity
RS54596B1 (en) * 2009-12-10 2016-08-31 F. Hoffmann-La Roche Ag Antibodies Binding to Extracellular Domain 4 of Human CSF1R and Their Use
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
BR112013033944A2 (pt) * 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano

Also Published As

Publication number Publication date
AU2016282877A8 (en) 2018-01-18
IL256135A (en) 2018-02-28
AU2016282877A1 (en) 2018-01-04
WO2016207312A1 (en) 2016-12-29
ZA201708074B (en) 2018-11-28
US20180222985A1 (en) 2018-08-09
KR20180012873A (ko) 2018-02-06
CN107847592A (zh) 2018-03-27
BR112017027614A2 (pt) 2018-08-28
EP3313442B1 (en) 2019-10-16
CR20170537A (es) 2018-02-20
EP3313442A1 (en) 2018-05-02
JP6811733B2 (ja) 2021-01-13
JP2018525339A (ja) 2018-09-06
PE20181050A1 (es) 2018-07-03
RU2018102575A (ru) 2019-07-25
MX2017016651A (es) 2018-05-14
CN107847592B (zh) 2022-01-21
CA2987716A1 (en) 2016-12-29
HK1252860A1 (zh) 2019-06-06

Similar Documents

Publication Publication Date Title
CL2017003295A1 (es) Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CL2017002401A1 (es) Anticuerpos contra icos
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
AR101697A1 (es) Terapia de combinación de inmunocitocinas variantes de il-2 dirigidas a tumores y anticuerpos contra pd-l1 humana
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
BR112015032224A2 (pt) anticorpos anti-fcrh5
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
PE20231655A1 (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo